ATE544774T1 - Rnai-modulation von mll-af4 und verwendungen dafür - Google Patents

Rnai-modulation von mll-af4 und verwendungen dafür

Info

Publication number
ATE544774T1
ATE544774T1 AT05854523T AT05854523T ATE544774T1 AT E544774 T1 ATE544774 T1 AT E544774T1 AT 05854523 T AT05854523 T AT 05854523T AT 05854523 T AT05854523 T AT 05854523T AT E544774 T1 ATE544774 T1 AT E544774T1
Authority
AT
Austria
Prior art keywords
mll
rnai modulation
rnai
modulation
downregulation
Prior art date
Application number
AT05854523T
Other languages
English (en)
Inventor
Olaf Heidenreich
Hans-Peter Vornlocher
Philipp Hadwiger
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE544774T1 publication Critical patent/ATE544774T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Control Of El Displays (AREA)
  • Inductance-Capacitance Distribution Constants And Capacitance-Resistance Oscillators (AREA)
AT05854523T 2004-12-14 2005-12-14 Rnai-modulation von mll-af4 und verwendungen dafür ATE544774T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63593604P 2004-12-14 2004-12-14
US66839205P 2005-04-05 2005-04-05
US69841405P 2005-07-12 2005-07-12
PCT/US2005/045827 WO2006066158A2 (en) 2004-12-14 2005-12-14 Rnai modulation of mll-af4 and uses thereof

Publications (1)

Publication Number Publication Date
ATE544774T1 true ATE544774T1 (de) 2012-02-15

Family

ID=36588628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854523T ATE544774T1 (de) 2004-12-14 2005-12-14 Rnai-modulation von mll-af4 und verwendungen dafür

Country Status (7)

Country Link
US (4) US7361752B2 (de)
EP (1) EP1824872B1 (de)
JP (2) JP2008523157A (de)
AT (1) ATE544774T1 (de)
AU (1) AU2005316384B2 (de)
CA (1) CA2590768A1 (de)
WO (1) WO2006066158A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP2008523157A (ja) * 2004-12-14 2008-07-03 アルナイラム ファーマシューティカルズ インコーポレイテッド ＭＬＬ−ＡＦ４のＲＮＡｉ調節およびその使用方法
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) * 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
AU2006302496A1 (en) * 2005-10-05 2007-04-19 The Ohio State University Research Foundation WWOX gene, vectors containing the same, and uses in treatment of cancer
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CN102943108B (zh) 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
EP1969147B1 (de) 2006-01-05 2014-07-30 The Ohio State University Research Foundation mikro-RNA-basierte verfahren zur Diagnose von Magenkrebs
CN101448958A (zh) 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2369017B8 (de) 2006-07-13 2014-03-12 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von Krankheiten im Zusammenhang mit dem Dickdarm
ES2374446T3 (es) 2006-09-19 2012-02-16 The Ohio State University Research Foundation Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181.
AU2007314212B2 (en) 2006-11-01 2014-05-29 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services MicroRNA expression signature for predicting survival and metastases in Hepatocellular carcinoma
AU2008211142A1 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
CN104195226B (zh) * 2007-04-30 2017-01-11 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
JP5690588B2 (ja) * 2007-06-08 2015-03-25 アメリカ合衆国 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
CA2690749A1 (en) 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
ES2496172T3 (es) * 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
ES2562078T3 (es) * 2007-08-22 2016-03-02 The Ohio State University Research Foundation Métodos y composiciones para inducir la desregulación de la fosforilación de EphA7 y ERK en leucemias agudas humanas
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
ES2647538T3 (es) 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
CN103898069A (zh) 2007-10-26 2014-07-02 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
JP2011505143A (ja) * 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009108856A2 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
AU2009219197B2 (en) * 2008-02-28 2014-04-10 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dep. Of Health And Human Services MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
EP2329023B1 (de) * 2008-08-28 2016-07-27 Council of Scientific & Industrial Research Zusammensetzungen und verfahren zur zuführung proteincodierender rnas zur korrektur einer mitochondrienfehlfunktion
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
KR20180026571A (ko) 2009-05-27 2018-03-12 셀렉타 바이오사이언시즈, 인크. 면역조절제를 ｐＨ 감응성으로 방출하는 표적화된 합성 나노운반체
JP5875976B2 (ja) 2009-06-01 2016-03-02 ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド 多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法
WO2011014704A2 (en) 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102803511A (zh) 2009-11-23 2012-11-28 俄亥俄州立大学 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法
EP2553019A1 (de) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modifizierte polymere zur freisetzung von polynukleotiden, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
MX2012013713A (es) 2010-05-26 2013-01-28 Selecta Biosciences Inc Composiciones de nanovehiculos con adyuvante no acoplado.
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
WO2012082894A1 (en) * 2010-12-17 2012-06-21 Arrowhead Research Corporation Compositions and methods for inhibiting expression of mll genes
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
JP2015501843A (ja) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
CA2866052A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
MX2019014800A (es) 2017-07-06 2020-02-10 Arrowhead Pharmaceuticals Inc Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso.
CN107964536B (zh) * 2018-01-19 2021-10-22 上海交通大学医学院附属瑞金医院 一种实现人的诱导多能干细胞来源的造血干祖细胞强效体内移植的方法
WO2024059618A2 (en) 2022-09-13 2024-03-21 Arsenal Biosciences, Inc. Immune cells having co-expressed tgfbr shrnas
WO2024059824A2 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7045292B2 (en) * 1998-03-25 2006-05-16 University Of Manitoba Method and marker for identification of pre-malignancy and malignancy and therapeutic intervention
EP1272630A2 (de) * 2000-03-16 2003-01-08 Genetica, Inc. Methoden und zusammensetzungen zur interferenz durch rna
HU230458B1 (hu) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
EP1386004A4 (de) 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
ATE479752T1 (de) 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
AU2004232964B2 (en) 2003-04-17 2011-09-22 Alnylam Pharmaceuticals, Inc. Protected monomers
EP2669377A3 (de) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modifizierte iRNA-Wirkstoffe
JP2008523157A (ja) * 2004-12-14 2008-07-03 アルナイラム ファーマシューティカルズ インコーポレイテッド ＭＬＬ−ＡＦ４のＲＮＡｉ調節およびその使用方法
CA2690749A1 (en) * 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing

Also Published As

Publication number Publication date
US7674779B2 (en) 2010-03-09
WO2006066158A3 (en) 2007-04-19
US20080233584A1 (en) 2008-09-25
US20120010267A1 (en) 2012-01-12
CA2590768A1 (en) 2006-06-22
US8034793B2 (en) 2011-10-11
AU2005316384B2 (en) 2012-02-09
US7361752B2 (en) 2008-04-22
EP1824872A4 (de) 2008-11-26
WO2006066158A2 (en) 2006-06-22
JP2008523157A (ja) 2008-07-03
AU2005316384A1 (en) 2006-06-22
US20100256218A1 (en) 2010-10-07
JP2011254840A (ja) 2011-12-22
EP1824872B1 (de) 2012-02-08
US20060166918A1 (en) 2006-07-27
EP1824872A2 (de) 2007-08-29

Similar Documents

Publication Publication Date Title
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
EA200800868A1 (ru) Модуляция экспрессии глюкокортикоидного рецептора
WO2007053696A3 (en) Rnai inhibition of influenza virus replication
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
DK2318032T3 (da) Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
EA201492119A1 (ru) Композиции и способы для модулирования экспрессии apoa1 и abca1
EA200800869A1 (ru) Модуляция экспрессии рецептора глюкагона
ECSP067014A (es) Modulación de producción de inmunoglobulina y trastornos atópicos
MX2010003606A (es) Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
WO2010033771A3 (en) Modulators of hsp70/dnak function and methods of use thereof
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов
EP1814597A4 (de) Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen
BRPI0516576A (pt) vetores quiméricos
EA200970472A1 (ru) Замещенные пиразолы, композиции, их содержащие, способ получения и применение
CL2004000064A1 (es) Compuestos derivados de alquilamido piperdinas, composicion farmaceutica, utiles para tratar depresion, desorden bipolar, fobia social, incontinencia urinaria, obesidad, bulimia, anorexia nerviosa y otros.
WO2009071680A3 (en) Rna antagonist compounds for the modulation of mcl-1